BioVie Therapeutics' Bezisterim Meets Phase 2 Endpoints in Early Parkinson's Disease

BIVI BioVie Inc

$1.44 0.00%

View chart & analysis →

1. 1BioVie (BIVI) announced that its candidate bezisterim met pre-defined endpoints in the Phase 2 SUNRISE-PD trial in early Parkinson's disease.
2. 2While the majority of the bezisterim group showed improvement on EPNIC-15, the placebo group moved in the opposite direction, and in patients with platelets above 230 x10³/µL, the treatment demonstrated statistically significant superiority across all clinical measures.
3. 3The company noted that tolerability was comparable to placebo, with adverse events reported at 39.3% for bezisterim versus 51.7% for placebo, and emphasized the potential of its differentiated approach targeting the underlying biology of the disease.

Source Proactive +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →